Search

A meta-analysis and trial sequential analysis was conducted to evaluate the risk of COVID-19 in patients with atopic dermatitis (AD). Seven studies were included in the analysis, which showed that the risk of COVID-19 in AD patients was similar to that of control subjects. The analysis also suggested that AD patients may have better hygiene habits and reduced social interaction, which could contribute to a lower infection risk. However, the impact of AD on the severity of COVID-19 was not analyzed. It is recommended that AD patients continue to practice prevention measures and consider teledermatology for follow-up visits. [Extracted from the article]

This article is a meta-analysis and trial sequential analysis that evaluates the risk of bone fractures in patients with atopic dermatitis (AD). The study includes four high-quality studies from different regions, with a total of 409,366 AD patients and 1,704,553 control subjects. The analysis shows that AD patients have an elevated risk of bone fractures compared to non-AD control subjects, with a risk ratio of 1.10. The study suggests that clinicians should be aware of the increased fracture risk in AD patients and further research is needed to understand the mechanisms behind this association. [Extracted from the article]

Objective: To evaluate the association between IL-25, IL-33 and AD more generally. Methods: Databases, including PubMed, Web of Science, EMBASE, Scopus, CNKI and Sinomed were searched. Based on the criteria, publications were collected. The evaluation of study quality was through Newcastle-Ottawa Scale (NOS). Fixed or random effect model was selected according to the between-study heterogeneity to evaluate the association. The analysis procedure and the construction plots were using Review Manager 5.3 software. Results: Six studies were included. A total of 282 subjects were included from four studies to analyze the association between IL-25 and AD. The level of IL-25 was significantly elevated in AD patients, comparing with the control subjects (SMD = 0.89, 95% CI: 0.64, 1.14, p < 0.05). For IL-33, a total of 247 subjects were included from two studies, and the level of IL-33 was also significantly elevated in AD patients comparing to the control subjects (SMD = 0.49, 95% CI: 0.19, 0.80, p < 0.05). Conclusions: The serum levels of IL-25, IL-33 are elevated in AD patients of this study. The IL-25 and IL-33 are significantly associated with the risk of AD. Further studies with larger samples, in multiple countries and focused on different age groups are need. [ABSTRACT FROM AUTHOR]